Cargando…

Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer

The present study aimed to evaluate the optimal timing of radium-223 chloride (Ra-223) administration among patients with bone metastasis from castration-resistant prostate cancer (BmCRPC). Patients, who were diagnosed with BmCRPC and treated with Ra-223 therapy between October, 2016 and January, 20...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makita, Kenji, Hamamoto, Yasushi, Kanzaki, Hiromitsu, Yamashita, Natsumi, Nagasaki, Kei, Kido, Teruhito, Miura, Noriyoshi, Saika, Takashi, Hashine, Katsuyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391592/ https://www.ncbi.nlm.nih.gov/pubmed/37533801 http://dx.doi.org/10.3892/mi.2023.98

Ejemplares similares

Relationship between seminal vesicle displacement and distribution of hydrogel spacer within the perirectal space in prostate radiotherapy
por: Makita, Kenji, et al.
Publicado: (2023)

Chemoradiotherapy for Small-Cell Prostate Carcinoma: A Case Report
por: Makita, Kenji, et al.
Publicado: (2023)

Prognostic assessment of patients who receive radiotherapy for bone metastases from breast cancer
por: Makita, Kenji, et al.
Publicado: (2023)

Factors Affecting Survival and Local Control in Patients with Bone Metastases Treated with Radiotherapy
por: Makita, Kenji, et al.
Publicado: (2023)

Factors affecting local control of bone metastases from radioresistant tumors treated with palliative external beam radiotherapy
por: Makita, Kenji, et al.
Publicado: (2023)

Impact of digital positron emission tomography/computed tomography on the delineation of clinical target volume in advanced lung cancer
por: Makita, Kenji, et al.
Publicado: (2023)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015)

Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study
por: Makita, Kenji, et al.
Publicado: (2021)

Local control after palliative external beam radiotherapy for bone metastases in patients with favorable prognosis
por: Makita, Kenji, et al.
Publicado: (2022)

Local control of bone metastasis treated with palliative radiotherapy in patients with lung cancer: An observational retrospective cohort study
por: Makita, Kenji, et al.
Publicado: (2023)

An easy tool to predict survival in patients with bone metastatic lung cancer treated with palliative radiotherapy
por: Makita, Kenji, et al.
Publicado: (2023)

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015)

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)

Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
por: Aprile, Carlo, et al.
Publicado: (2016)

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017)

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2018)

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: Vidal, Monica, et al.
Publicado: (2020)

Radiation-induced enterocolitis after combination therapy with palliative radiotherapy and immune checkpoint inhibitors in patients with metastatic lung cancer
por: Makita, Kenji, et al.
Publicado: (2022)

Clinical significance of completion of radium-223 treatment and acute adverse events in patients with metastatic castration-resistant prostate cancer
por: Takeda, Kazuya, et al.
Publicado: (2023)

Administration of radium‐223 and the prognosis in Japanese bone metastatic castration‐resistant prostate cancer patients: A large database study
por: Kawahara, Takashi, et al.
Publicado: (2022)

Risk factors for pericardial effusion after chemoradiotherapy for thoracic esophageal cancer—comparison of four-field technique and traditional two opposed fields technique
por: Takata, Noriko, et al.
Publicado: (2018)

Radium-223 Chloride: A New Treatment Option for Metastatic Castration-Resistant Prostate Carcinoma
por: Pinto, Álvaro, et al.
Publicado: (2012)

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223
por: Mukherji, Deborah, et al.
Publicado: (2014)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases
por: Kapoor, Anil, et al.
Publicado: (2019)

Analysis of Unusual Adverse Effects After Radium-223 Dichloride  Administration
por: Frantellizzi, Viviana, et al.
Publicado: (2020)

Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation
por: Nguyen, Nghi C., et al.
Publicado: (2016)

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
por: Roviello, Giandomenico, et al.
Publicado: (2018)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

Editorial Comment: Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
por: van der Zande, Kim, et al.
Publicado: (2021)

Impact of neutrophil-to-lymphocyte ratio throughout the course of chemoradiotherapy on overall survival and distant failure in unresectable stage III non-small cell lung cancer
por: Kanzaki, Hiromitsu, et al.
Publicado: (2021)

Real-Time Scintigraphic Assessment of Intravenous Radium-223 Administration for Quality Control
por: Wright, Chadwick L., et al.
Publicado: (2015)

Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases
por: Ogawa, Kazuma, et al.
Publicado: (2020)

Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer
por: Renzulli, Joseph F, et al.
Publicado: (2015)

Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
por: Nilsson, Sten
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j2d97evkare5kmsd9e3lq0p8ap